Community Considerations in Relapsed/Refractory Multiple Myeloma: Current and Developing Anti-BCMA Therapies
Post-Test/Evaluation
Questions marked with a
*
are required
26%
Contact Information
First Name
Last Name
Email Address
Credentials/Degree (MD, DO, RN, etc.)
Date of Participation
Month
Jan
Feb
Mar
Apr
May
Jun
Jul
Aug
Sep
Oct
Nov
Dec
Day
01
02
03
04
05
06
07
08
09
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
Year
2018
2019
2020
2021
2022
2023
2024
2025
Are you a Physician?
Yes
No
GR is a 72-year-old male patient with multiple myeloma who is frustrated with therapy after receiving 3 prior lines of treatment and experienced relapse each time. He is not a candidate for stem cell transplant. He states that he had a brother with leukemia who was cured and wants to know why myeloma is so difficult to eradicate. Which of the following reasons is/are explanations of why multiple myeloma is a difficult hematologic malignancy to treat from the perspective of treatment resistance?
A. Healthy plasma cells produce antibodies that enable adaptive immunity, so they are very hardy cells that are difficult to eliminate from the body when malignant
B. Immature malignant B cells are resistant to chemotherapy
C. Plasma cells are sequestered in bone marrow and are difficult to reach
D. A and B
E. A, B, and C
Which of the following treatments are common mechanisms of frontline management of multiple myeloma that are also used in the management of relapsed/refractory multiple myeloma?
A. SLAMF7 inhibitors, immunomodulatory drugs
B. Anti-CD38 antibodies and selinexor
C. Single-agent immunomodulatory drugs
D. Proteosome inhibitors, immunomodulatory drugs, corticosteroids, and combinations
E. None of the above
Which of the following most accurately describes the mechanism of BCMA-targeted bispecific antibodies in the management of relapsed/refractory multiple myeloma that has failed multiple prior regimens?
A. Targets CD3 on T cells and BCMA on malignant B cells
B. Targets CD3 on malignant B cells and BCMA on T cells
C. Targets CD8 on malignant B cells and BCMA on T cells
D. Targets CD8 on T cells and BCMA on malignant B cells
E. None of the above statements are true
Start
Powered by
QuestionPro
Loading...
close
drag_indicator
close
Yes
Cancel
Continue
Answer Question
Continue Without Answering
Keep Data
Discard
close